Medprin Regenerative Medical Technologies (301033.SZ) has forecasted a pre-increase, with an expected annual net profit of 70-80 million RMB, a year-on-year increase of 71.24%-95.71%.

Medprin Regenerative Medical Technologies (301033.SZ) disclosed its annual performance forecast for the year 2024, with the company expecting a net profit attributable to shareholders of the listed company of 70-80 million yuan, a year-on-year increase of 71.24%-95.71%; and a net profit after deducting non-recurring gains and losses of 60-70 million yuan, a year-on-year increase of 61.15%-88.01%.